You are here

Article Text

Article menu
Download PDFPDF
Gene of the month
Gene of the month: NKX3.1
  1. Jon Griffin1,2,
  2. Yuqing Chen3,
  3. James W F Catto4,5,
  4. Sherif El-Khamisy2
  1. 1 Histopathology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  2. 2 Healthy Lifespan and Neuroscience Institute, Department of Biosciences, The University of Sheffield, Sheffield, UK
  3. 3 Department of Medicine, University of Cambridge, Cambridge, Cambridgeshire, UK
  4. 4 Academic Urology Unit, The University of Sheffield, Sheffield, UK
  5. 5 Urology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  1. Correspondence to Dr Jon Griffin, Histopathology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; jon.griffin{at}nhs.net

Abstract

NKX3.1 is a multifaceted protein with roles in prostate development and protection from oxidative stress. Acting as a pioneer factor, NKX3.1 interacts with chromatin at enhancers to help integrate androgen regulated signalling. In prostate cancer, NKX3.1 activity is frequently reduced through a combination of mutational and post-translational events. Owing to its specificity for prostate tissue, NKX3.1 has found use as an immunohistochemical marker in routine histopathology practice.

  • prostate
  • immunohistochemistry
  • receptors
  • steroid

http://dx.doi.org/10.1136/jclinpath-2021-208073

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Handling editor Runjan Chetty.

    • Contributors JG and YC performed the literature search and created the figures, all authors wrote and edited the manuscript.

    • Funding JG is funded by a Clinical PhD Fellowship from The Pathological Society of Great Britain and Ireland, and The Jean Shanks Foundation (JSPS-CPHD-2018–01). JWFC is funded by an NIHR Research Professorship. SE-K is funded by a Wellcome Trust Investigator Award (103844) and a Lister Institute of Preventative Medicine Fellowship (137661).

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.